Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 10/2014

01-10-2014 | Commentary

Protein Engineering for Improved Pharmacologic Characteristics of Established Monoclonal Antibody-Based Therapeutics

Author: Bernd Meibohm

Published in: Clinical Pharmacokinetics | Issue 10/2014

Login to get access

Excerpt

Since the widespread clinical introduction of chimeric, humanized and human monoclonal antibodies more than 15 years ago, monoclonal antibody based therapeutics have conquered substantial ground as major players and in some indications even cornerstones in the pharmacotherapeutic management of a variety of serious medical conditions [1]. …
Literature
1.
Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59.PubMedCrossRef
2.
3.
Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137–46.PubMedCrossRef
4.
Feagan BG, Choquette D, Ghosh S, Gladman DD, Ho V, Meibohm B, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177–83.PubMedCrossRef
5.
Othman AA, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014. doi:10.​1007/​s40262-014-0159-9.
6.
7.
Hartman TE, Sauer PW, Burky JE, Wesson MC, Huang PY, Robinson TJ, et al., inventors. DAC HYP compositions and methods. US patent US 2012/0301429 A1. 29 Nov 2012.
Metadata
Title
Protein Engineering for Improved Pharmacologic Characteristics of Established Monoclonal Antibody-Based Therapeutics
Author
Bernd Meibohm
Publication date
01-10-2014
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2014
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-014-0186-6

Other articles of this Issue 10/2014

Clinical Pharmacokinetics 10/2014 Go to the issue

Erratum

Erratum to: Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir Disposition

Review Article

Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System

Original Research Article

Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

Review Article

Review of Evidence for Measuring Drug Concentrations of First-Line Antitubercular Agents in Adults

Original Research Article

Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years

Original Research Article

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration